Last reviewed · How we verify

Marcaine ½%

Randers Regional Hospital · FDA-approved active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local infiltration anesthesia, Peripheral nerve blocks, Regional anesthesia (epidural, spinal).

At a glance

Generic nameMarcaine ½%
SponsorRanders Regional Hospital
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine reversibly inhibits sodium influx into nerve fibers by binding to sodium channels from the intracellular side, thereby stabilizing the neuronal membrane and preventing depolarization. This action is concentration-dependent and affects sensory nerves before motor nerves. The 0.5% formulation provides moderate anesthetic potency suitable for infiltration, nerve blocks, and regional anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: